概括
与化学疗法相比,尼沃卢马布加上伊皮利马布在高级非小细胞肺癌患者中显示出更高的整体存活率. 这种双重免疫检查点抑制导致了显著的瘤缩和长期生存益处.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 临床试验 临床试验
背景情况:
- 晚期非小细胞肺癌 (NSCLC) 仍然是一个重大的健康挑战.
- 化疗一直是标准的第一线治疗,但长期疗效受到限制.
- 免疫检查点抑制剂为NSCLC提供了一个有希望的治疗途径.
研究的目的:
- 评估尼沃卢马布加上伊皮利穆马布的长期整体生存 (OS) 结果与晚期非小细胞肺癌患者的化疗相比.
- 评估瘤缩与双重免疫检查点抑制的长期生存益处之间的相关性.
主要方法:
- 检查机 227 第 1 部分试验.
- 最少6年的随访时间.
- 尼沃卢马布和伊皮利穆马布联合治疗与化疗作为先进NSCLC的第一线治疗的比较.
主要成果:
- 与化疗相比,Nivolumab加上ipilimumab在至少6年的随访中显示出更高的整体存活率.
- 双重免疫检查点抑制导致瘤缩小.
- 深度瘤反应与长期的OS益处有很强的相关性.
结论:
- 尼沃卢马布加上伊皮利穆马布是一种持久的第一线治疗选择,用于晚期非小细胞肺癌.
- 通过双重免疫检查点抑制,可以实现持久的反应和长期生存益处.
- 瘤缩是治疗nivolumab和ipilimumab的患者长期存活的强有力的指标.
更多相关视频
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.5K
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
10.6K
相关概念视频
01:27Tumor Immunotherapy
554
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
554
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K